Business
Final Results, Share Buyback & Leadership Changes
Hikma Pharmaceuticals Plc reported a 7% increase in Group revenue to $3,349 million for the year ended December 31, 2025, with profit attributable to shareholders rising 12% to $402 million, though operating profit saw an 11% decline to $542 million, largely due to a legal settlement. The company announced a $250 million share buyback program for 2026 and a 5% increase in its total dividend to 84 cents per share, reflecting strong cash flow generation. Leadership changes were also announced, including the CEO focusing solely on that role and new appointments to Deputy CEO positions. The company provided 2026 guidance expecting Group revenue growth of 2% to 4% and Group core operating profit between $720 million and $770 million. Disclaimer*
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n\nHikma delivers Group revenue and profit growth and announces share buyback and leadership changes\n \nThis announcement contains inside information.\n \nLondon, 26 February 2026 - Hikma Pharmaceuticals PLC ('Hikma' or 'Group'), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025.\n \nSaid Darwazah, Chief Executive Officer (CEO) of Hikma, said: \n \n\"Strong momentum in our Branded and Hikma Rx businesses and growth in all our geographies enabled us to deliver Group revenue and profit growth in line with guidance, and resilient margins. While our Injectables business has experienced some challenges, we are taking clear steps to address these and we are confident in the longer-term prospects for this business.\nThe leadership changes that we are announcing today will enable us to execute the Group strategy with more agility and greater accountability. To support this, I will relinquish my Executive Chairman responsibilities and focus fully on being CEO.\nWe are confident in the guidance we have set for 2026, which assumes continued strong momentum in Branded and Hikma Rx and increased investment in Injectables. Looking ahead, our focus is on delivering sustainable profit growth. I remain optimistic for the future and am committed to returning to the out-performance we and our shareholders expect. Reflecting this, and our strong cash flow generation, we have increased our total dividend by 5% and are announcing a $250 million share buyback, which we will execute over the course of the year.\"\n \n\n\n\n\nReported results (statutory)\n \n\n\n 2025\n$ million\n\n\n2024\n$ million\n\n\nChange\n\n\nConstant currency[1]\nchange\n\n\n\n\nRevenue\n\n\n3,349\n\n\n3,127\n\n\n7%\n\n\n6%\n\n\n\n\nOperating profit\n\n\n542\n\n\n612\n\n\n(11)%\n\n\n(12)%\n\n\n\n\nProfit attributable to shareholders\n\n\n402\n\n\n359\n\n\n12%\n\n\n13%\n\n\n\n\nCashflow from operating activities\n\n\n436\n\n\n564\n\n\n(23)%\n\n\n-\n\n\n\n\nBasic earnings per share (cents)\n\n\n182\n\n\n162\n\n\n12%\n\n\n13%\n\n\n\n\nTotal dividend per share (cents)\n\n\n84\n\n\n80\n\n\n5%\n\n\n-\n\n\n\n\n \n\n\n\n\nCore results[2] (underlying)\n \n\n\n 2025\n$ million\n \n\n\n2024\n$ million\n\n\nChange\n\n\nConstant currency1\nchange\n\n\n\n\nCore revenue\n...